ES2721907T3 - Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal - Google Patents

Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal Download PDF

Info

Publication number
ES2721907T3
ES2721907T3 ES12832845T ES12832845T ES2721907T3 ES 2721907 T3 ES2721907 T3 ES 2721907T3 ES 12832845 T ES12832845 T ES 12832845T ES 12832845 T ES12832845 T ES 12832845T ES 2721907 T3 ES2721907 T3 ES 2721907T3
Authority
ES
Spain
Prior art keywords
renal
prognosis
diagnosis
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12832845T
Other languages
English (en)
Spanish (es)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astute Medical Inc
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Application granted granted Critical
Publication of ES2721907T3 publication Critical patent/ES2721907T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
ES12832845T 2011-08-26 2012-08-24 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal Active ES2721907T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528003P 2011-08-26 2011-08-26
US201161528000P 2011-08-26 2011-08-26
PCT/US2012/052298 WO2013043310A1 (en) 2011-08-26 2012-08-24 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
ES2721907T3 true ES2721907T3 (es) 2019-08-06

Family

ID=47914751

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12832845T Active ES2721907T3 (es) 2011-08-26 2012-08-24 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal

Country Status (16)

Country Link
US (2) US9459261B2 (enExample)
EP (2) EP2748605B1 (enExample)
JP (2) JP2014529073A (enExample)
KR (1) KR20140074307A (enExample)
CN (2) CN106443011A (enExample)
AU (1) AU2012312907A1 (enExample)
BR (1) BR112014004389A2 (enExample)
CA (1) CA2846602A1 (enExample)
EA (1) EA201490384A1 (enExample)
ES (1) ES2721907T3 (enExample)
IN (1) IN2014MN00377A (enExample)
MX (1) MX346096B (enExample)
PL (1) PL2748605T4 (enExample)
PT (1) PT2748605T (enExample)
TR (1) TR201903235T4 (enExample)
WO (1) WO2013043310A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3783363A1 (en) 2008-10-21 2021-02-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290387A1 (ru) 2009-12-20 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EP2585827A4 (en) 2010-06-23 2013-12-04 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
WO2013043310A1 (en) * 2011-08-26 2013-03-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2788759B1 (en) 2011-12-08 2019-02-20 Astute Medical, Inc. Methods and uses for diagnosis of renal injury and renal failure
EP3734280B8 (en) 2013-01-17 2022-08-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10983136B2 (en) * 2013-01-28 2021-04-20 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
WO2016113720A1 (en) * 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
US11261257B2 (en) 2013-01-28 2022-03-01 Diasorin S.P.A. Methods for detecting 1,25-dihydroxyvitamin D and related antibodies
ES2696075T3 (es) 2013-01-28 2019-01-14 Diasorin S P A Procedimiento y kit para detectar 1,25-dihidroxivitamina D y anticuerpos relacionados
WO2015084939A1 (en) 2013-12-03 2015-06-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT3210018T (pt) 2014-10-20 2021-10-04 Astute Medical Inc Métodos e composições para o diagnóstico e prognóstico de lesão renal e insuficiência renal
WO2016164854A1 (en) * 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105466984B (zh) * 2016-01-14 2018-12-28 郑以山 用于肾脏非显性损伤的预警装置及其使用方法
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
MX2019008260A (es) 2017-01-12 2020-01-27 Astute Medical Inc Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP7315466B2 (ja) 2017-04-05 2023-07-26 アスチュート メディカル,インコーポレイテッド 生体試料中において改善した性能を有する、timp2に関するアッセイ
AU2019272960B2 (en) 2018-05-24 2024-12-12 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
CN109251956A (zh) * 2018-09-18 2019-01-22 青岛大学 糖尿病大鼠胰岛内MyD88 mRNA表达及黄芪的调节作用
WO2020092909A1 (en) * 2018-11-02 2020-05-07 Prevencio, Inc. Prognostic and diagnostic methods for risk of acute kidney injury
CN114113575B (zh) * 2020-08-28 2023-06-02 菲鹏生物股份有限公司 标记复合物及其制备方法与应用
CN116434960B (zh) * 2023-06-13 2023-10-13 中国人民解放军总医院 一种心源性休克临床决策支持系统、设备及可存储介质
WO2025033619A1 (ko) * 2023-08-07 2025-02-13 경상국립대학교병원 신 대체요법 개시 결정을 위한 정보 제공 방법 및 이의 결정을 위한 말기 신질환 진단용 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
FI934437L (fi) 1991-04-10 1993-11-22 Biosite Diagnostics Inc Crosstalk-inhibitorer och deras anvaendning
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CN1791797A (zh) * 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
EP2083270B1 (en) 2003-03-27 2019-06-12 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
WO2005002416A2 (en) * 2003-06-04 2005-01-13 Joslin Diabetes Center, Inc. Predictors of renal disease
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
CN101557825A (zh) * 2005-08-19 2009-10-14 森托科尔公司 抗蛋白酶解的抗体制剂
WO2007144781A2 (en) * 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
US8609812B2 (en) * 2007-03-26 2013-12-17 Novartis Ag Use of β-2-microglobulin to assess glomerular alterations and damage in the kidney
US20100304413A1 (en) 2007-11-15 2010-12-02 Lars Otto Uttenthal Diagnostic use of individual molecular forms of a biomarker
CA2716854A1 (en) 2008-02-29 2009-09-03 National University Corporation Nagoya University Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker
BRPI0917711A2 (pt) * 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
EP2324354B1 (en) * 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
EP3783363A1 (en) * 2008-10-21 2021-02-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2011004767A (es) * 2008-11-10 2011-09-06 Astute Medical Inc Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
US9229010B2 (en) * 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RU2559569C2 (ru) * 2009-06-02 2015-08-10 Байокрейтс Лайф Сайенсиз Аг Новые биомаркеры для оценки болезней почек
CA2770393A1 (en) * 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105004864B (zh) * 2009-09-18 2017-11-03 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后方法和组合物
MX2009012633A (es) * 2009-11-23 2011-05-24 Univ Mexico Nacional Autonoma Metodo de diagnostico para detectar la lesion renal aguda a traves del uso de la proteina de choque termico de 72 kda como un biomarcador sensible.
EA201290387A1 (ru) * 2009-12-20 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
KR20140051754A (ko) 2010-02-26 2014-05-02 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
WO2013043310A1 (en) * 2011-08-26 2013-03-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
BR112014004389A2 (pt) 2017-03-28
EP2748605B1 (en) 2018-12-05
MX346096B (es) 2017-03-07
PT2748605T (pt) 2019-05-03
CA2846602A1 (en) 2013-03-28
IN2014MN00377A (enExample) 2015-06-19
EP3489690A1 (en) 2019-05-29
PL2748605T3 (pl) 2019-08-30
AU2012312907A1 (en) 2014-03-13
NZ706242A (en) 2016-07-29
EP2748605A1 (en) 2014-07-02
WO2013043310A1 (en) 2013-03-28
US9459261B2 (en) 2016-10-04
US9784750B2 (en) 2017-10-10
TR201903235T4 (tr) 2019-03-21
JP2014529073A (ja) 2014-10-30
US20140213477A1 (en) 2014-07-31
CN103874923A (zh) 2014-06-18
JP2017032586A (ja) 2017-02-09
EA201490384A1 (ru) 2014-08-29
NZ621716A (en) 2016-04-29
PL2748605T4 (pl) 2019-08-30
CN103874923B (zh) 2016-09-14
CN106443011A (zh) 2017-02-22
MX2014002146A (es) 2014-08-21
US20170016917A1 (en) 2017-01-19
EP2748605A4 (en) 2015-12-02
KR20140074307A (ko) 2014-06-17

Similar Documents

Publication Publication Date Title
ES2721907T3 (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
NZ705411A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CL2013003605A1 (es) Metodo para la evaluacion del riesgo de un evento tromboembólico en un sujeto que comprende determinar la presencia de serpin a 10 (inhibidor de la proteina z); kit que comprende reactivos para detectar serpin a 10.
EP3734280A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
MX2013010035A (es) Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).
MX2014003153A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
NZ598712A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AR097542A1 (es) Métodos y sistemas para la evaluación de la permeabilidad y la porosidad de la roca y la composición de los fluidos
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
AR060320A1 (es) Metodo para identificar y localizar problemas en losetas de drenaje
TR201903974T4 (tr) Tasnif makinesi için otomatik kusur tanı metodu ve cihazı.
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2015009914A (es) Dispositivos de recogida de sangre que contienen aditivos de inhibicion de la via de contacto.
MX383423B (es) Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal.
BR112018067292A2 (pt) métodos e composições para a detecção e o diagnóstico de doença renal e doença periodontal
HK1222888A1 (zh) 预测在淋巴结阳性早期乳癌复发风险的方法